BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7783332)

  • 1. [Detection of minimal residual disease by means of FISH and PCR methods and its clinical evaluation].
    Misawa S; Taniwaki M; Yokota S
    Rinsho Ketsueki; 1995 Apr; 36(4):293-8. PubMed ID: 7783332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
    Zwick D; Cooley L; Hetherington M
    Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
    Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
    Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical significance of interphase fluorescence in situ hybridization monitoring chimeric status after sex-mismatched allogeneic hematopoietic stem cell transplantation for leukemia].
    Liu Q; Song L; Zhang Y; Wei Y; Xu D; Sun J; Liu X; Xu B; Meng F; Zhou S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Apr; 22(2):212-5. PubMed ID: 15793790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of minimal residual disease in acute myeloid leukemia.
    Buccisano F; Maurillo L; Spagnoli A; Del Principe MI; Ceresoli E; Lo Coco F; Arcese W; Amadori S; Venditti A
    Curr Opin Oncol; 2009 Nov; 21(6):582-8. PubMed ID: 19667983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fluorescent in situ hybridization (FISH) and the polymerase chain reaction (PCR) for detection of residual neuroblastoma cells.
    Eckschlager T; McClain K
    Neoplasma; 1996; 43(5):301-3. PubMed ID: 8996548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
    Chan DW; Liang R; Kwong YL; Chan V
    Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring minimal residual disease in AML: the right time for real time.
    Jaeger U; Kainz B
    Ann Hematol; 2003 Mar; 82(3):139-47. PubMed ID: 12634945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of minimal residual diseases in B-cell tumors using PCR specific for the immunoglobulin heavy chain gene].
    Matolcsy A; Borbényi Z; Demeter J; Egyed M; Fekete S; Földi J; Gergely L; Kajtár P; Kelényi G; Kiss A; László T; Lehoczky D; Losonczy H; Nagy M; Pál K; Pálóczy K; Radványi G; Semsei I; Varga G; Udvardy M
    Orv Hetil; 2000 Jun; 141(25):1403-6. PubMed ID: 10934884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.
    Muñoz L; López O; Martino R; Brunet S; Bellido M; Rubiol E; Sierra J; Nomdedéu JF
    Haematologica; 2000 Jul; 85(7):704-10. PubMed ID: 10897122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The detection of minimal residual disease in leukemia by in vitro DNA amplification].
    Yokota S; Seriu T; Misawa S
    Rinsho Byori; 1991 Dec; 39(12):1298-307. PubMed ID: 1779467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.
    Nakao M; Janssen JW; Flohr T; Bartram CR
    Cancer Res; 2000 Jun; 60(12):3281-9. PubMed ID: 10866322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of minimal residual leukemia using polymerase chain reaction method].
    Naoe T
    Rinsho Byori; 1996 Jun; 44(6):535-40. PubMed ID: 8752731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR.
    Lal A; Kwan E; Haber M; Norris MD; Marshall GM
    Mol Cell Probes; 2001 Apr; 15(2):99-103. PubMed ID: 11292328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
    Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of minimal residual disease in acute leukemia.
    van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
    J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
    Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.